Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001706:Biopsy; D002330:Carmustine / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002699:Chlorambucil; D003609:Dactinomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D002330:Carmustine; D011241:Prednisone